nach oben

Inflammation

Erschienen in:

01.02.2013

Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis

verfasst von: Yu-Zhong Wang, Mei Yan, Fa-Fa Tian, Jun-Mei Zhang, Qun Liu, Huan Yang, Wen-Bin Zhou, Jing Li

Erschienen in: Inflammation | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Toll-like receptors (TLRs), the innate immunity components, have been demonstrated to participate in multiple autoimmune diseases. However, our knowledge of the roles of TLRs in myasthenia gravis (MG) is still scarce. In this study, we detected the mRNA expression of TLR1 to TLR10 in peripheral blood mononuclear cells (PBMCs) of MG patients and the healthy controls by quantitative real-time polymerase transcription chain reaction. Our data demonstrate that aberrant expressions of TLRs exist in the PBMCs of MG patients and of the total, expression level of TLR9 mRNA has significantly positive relation with the clinical severity of MG, which suggests that TLRs may be involved in the pathogenesis of MG.

Conti-Fine, B.M., M. Milani, and H.J. Kaminski. 2006. Myasthenia gravis: past, present, and future. The Journal of Clinical Investigation 116: 2843–2854.PubMedCrossRef

Lindstrom, J.M., M.E. Seybold, V.A. Lennon, S. Whittingham, and D.D. Duane. 1976. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054–1059.PubMedCrossRef

Hoch, W., J. McConville, S. Helms, J. Newsom-Davis, A. Melms, and A. Vincent. 2001. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 7: 365–368.PubMedCrossRef

McGettrick, A.F., and L.A. O'Neill. 2007. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. British Journal of Haematology 139: 185–193.PubMedCrossRef

Zarember, K.A., and P.J. Godowski. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. The Journal of Immunology 168: 554–561.PubMed

Takeda, K. and S. Akira. 2007. Toll-like receptors. Current Protocols in Immunology. Chapter 14: Unit 14 12.

Kawai, T., and S. Akira. 2007. TLR signaling. Seminars in Immunology 19: 24–32.PubMedCrossRef

Medzhitov, R., P. Preston-Hurlburt, E. Kopp, A. Stadlen, C. Chen, S. Ghosh, and C.A. Janeway Jr. 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Molecular Cell 2: 253–258.PubMedCrossRef

Devaraj, S., M.R. Dasu, J. Rockwood, W. Winter, S.C. Griffen, and I. Jialal. 2008. Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. The Journal of Clinical Endocrinology and Metabolism 93: 578–583.PubMedCrossRef

10.

Ehlers, M., H. Fukuyama, T.L. McGaha, A. Aderem, and J.V. Ravetch. 2006. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. The Journal of Experimental Medicine 203: 553–561.PubMedCrossRef

11.

Zeuner, R.A., K.J. Ishii, M.J. Lizak, I. Gursel, H. Yamada, D.M. Klinman, and D. Verthelyi. 2002. Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis and Rheumatism 46: 2219–2224.PubMedCrossRef

12.

Deng, Y.N., and W.B. Zhou. 2007. Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis. Neuroimmunomodulation 14: 337–343.PubMedCrossRef

13.

Wang, Y.Z., Q.H. Liang, H. Ramkalawan, Y.L. Wang, Y.F. Yang, W.B. Zhou, F. Tian, J. Li, and H. Yang. 2012. Expression of Toll-like receptors 2, 4 and 9 in Patients with Guillain-Barré syndrome. Neuroimmunomodulation 19: 60–68.PubMedCrossRef

14.

Wang, Y.Z., Q.H. Liang, H. Ramkalawan, W. Zhang, W.B. Zhou, B. Xiao, F.F. Tian, H. Yang, J. Li, Y. Zhang, and N.A. Xu. 2011. Inactivation of TLR9 by a suppressive oligodeoxynucleotides can ameliorate the clinical signs of EAN. Immunological Investigations 41: 171–182.PubMedCrossRef

15.

Bernasconi, P., M. Barberis, F. Baggi, L. Passerini, M. Cannone, E. Arnoldi, L. Novellino, F. Cornelio, and R. Mantegazza. 2005. Increased Toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. The American Journal of Pathology 167: 129–139.PubMedCrossRef

16.

Montero Vega, M.T., and A. de Andres Martin. 2008. Toll-like receptors: a family of innate sensors of danger that alert and drive immunity. Allergologia et Immunopathologia (Madr) 36: 347–357.CrossRef

17.

Jaretzki 3rd, A., R.J. Barohn, R.M. Ernstoff, H.J. Kaminski, J.C. Keesey, A.S. Penn, and D.B. Sanders. 2000. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16–23.PubMedCrossRef

18.

Osserman, K.E., and G. Genkins. 1971. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. The Mount Sinai Journal of Medicine 38: 497–537.

19.

Sharshar, T., S. Chevret, M. Mazighi, P. Chillet, G. Huberfeld, C. Berreotta, M. Houfani, and P. Gajdos. 2000. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. Journal of Neurology 247: 286–290.PubMedCrossRef

20.

Rozkova, D., R. Horvath, J. Bartunkova, and R. Spisek. 2006. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clinical Immunology 120: 260–271.PubMedCrossRef

21.

McCoy, C.E., S. Carpenter, E.M. Palsson-McDermott, L.J. Gearing, and L.A. O'Neill. 2008. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. The Journal of Biological Chemistry 283: 14277–14285.PubMedCrossRef

22.

Roelofs, M.F., M.H. Wenink, F. Brentano, S. Abdollahi-Roodsaz, B. Oppers-Walgreen, P. Barrera, P.L. van Riel, L.A. Joosten, D. Kyburz, W.B. van den Berg, and T.R. Radstake. 2009. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Annals of the Rheumatic Diseases 68: 1486–1493.PubMedCrossRef

23.

Kessel, A., R. Peri, T. Haj, A. Snir, G. Slobodin, E. Sabo, I. Rosner, Y. Shoenfeld, and E. Toubi. 2011. IVIg attenuates TLR-9 activation in B cells from SLE patients. Journal of Clinical Immunology 31: 30–38.PubMedCrossRef

24.

Marta, M., A. Andersson, M. Isaksson, O. Kampe, and A. Lobell. 2008. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. European Journal of Immunology 38: 565–575.PubMedCrossRef

25.

Muzio, M., N. Polentarutti, D. Bosisio, P.P. Manoj Kumar, and A. Mantovani. 2000. Toll-like receptor family and signalling pathway. Biochemical Society Transactions 28: 563–566.PubMed

26.

Chow, J.C., D.W. Young, D.T. Golenbock, W.J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. The Journal of Biological Chemistry 274: 10689–10692.PubMedCrossRef

27.

Lee, K.S., C.A. Scanga, E.M. Bachelder, Q. Chen, and C.M. Snapper. 2007. TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cellular Immunology 245: 103–110.PubMedCrossRef

28.

Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology 20: 709–760.PubMedCrossRef

29.

Riccardi, C., S. Bruscoli, and G. Migliorati. 2002. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacological Research 45: 361–368.PubMedCrossRef

30.

Chinenov, Y., and I. Rogatsky. 2007. Glucocorticoids and the innate immune system: crosstalk with the Toll-like receptor signaling network. Molecular and Cellular Endocrinology 275: 30–42.PubMedCrossRef

31.

Lepelletier, Y., R. Zollinger, C. Ghirelli, F. Raynaud, R. Hadj-Slimane, A. Cappuccio, O. Hermine, Y.J. Liu, and V. Soumelis. 2010. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood 116: 3389–3397.PubMedCrossRef

32.

Bhattacharyya, S., D.E. Brown, J.A. Brewer, S.K. Vogt, and L.J. Muglia. 2007. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109: 4313–4319.PubMedCrossRef

Titel: Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis
verfasst von: Yu-Zhong Wang
Mei Yan
Fa-Fa Tian
Jun-Mei Zhang
Qun Liu
Huan Yang
Wen-Bin Zhou
Jing Li
Publikationsdatum: 01.02.2013
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2013
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-012-9526-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Minocycline Treatment and Bone Marrow Mononuclear Cell Transplantation After Endothelin-1 Induced Striatal Ischemia

Anti-inflammatory Effects of Oleanolic Acid on LPS-Induced Inflammation In Vitro and In Vivo

Inhibition of LPS-Induced Retinal Microglia Activation by Naloxone Does Not Prevent Photoreceptor Death

Analysis of the Gene Expression Profile of Curcumin-Treated Kidney on Endotoxin-Induced Renal Inflammation

Severe Hyperglycemia Immediately After Allogeneic Hematopoietic Stem-Cell Transplantation is Predictive of Acute Graft-Versus-Host Disease

Involvement of Interleukin-17A in Pancreatic Damage in Rat Experimental Acute Necrotizing Pancreatitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin